2017, Number 2
<< Back Next >>
Bol Clin Hosp Infant Edo Son 2017; 34 (2)
Ventana de esteroide en niños con Leucemia Linfoblástica Aguda evaluada por factores pronósticos
Rendón-García H, Tamayo PG, Covarrubias-Espinoza G
Language: Spanish
References: 13
Page: 82-89
PDF size: 389.13 Kb.
ABSTRACT
The steroid window is a part of the initial therapy for Acute Lymphoblastic Leukemia (ALL) and it is used to evaluate the
medical response as a prognostic factor. The purpose is to identify the association of steroid response as a relapse predictor.
Transversal study in ALL patients, non probabilistic by convenience sampling, there were prognosis factors for ALL
including clinical risk, steroid response evaluated as good/bad responder. Descriptive analysis, the associations were examined
by a logistic regression model and Kaplan Meyer. 70 patients were studied, with a high group risk in a 59%, B-cell
Leukemia was presented in 92%, T-cell Leukemya in 6%, abnormal karyotype was registered in 30%. The response to
the steroid window, ‹1000 blasts in peripheral blood at 8th day of treatment, demonstrated 11% of bad responders, 89%
had a good response. Leucocytes ›50000 mm
3 registered an OR at 95% of 5 (CI 0.06-0.72); the OR for abnormal karyotype
at 95% was 3.7 (CI 1.04-12.82). The disease-free survival reported 55% for patients with good response to steroids
and 15% in bad responders. The steroid window is an important factor that evaluates the early response to the treatment.
REFERENCES
Lauten M, Moricke A, Beier R, Zimmermann M. Stanulla M, Meissner B, et al. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated the ALL-BFM 95 trial: diferential effects in precursor B-cell and T-cell leukemia. Haematologica. 2012; 97: 1048-1056.
Morcke A, Lauten M, Beier R, Odenwald E, Attarbaschi A, Niggli F, et al. Prediction of Outcome by Early Response in Childhood Acute Lymphoblastic Leukemia. Klin Padiatric. 2013; 225: S50-S56.
Riehm H, Reiter A, Schrappe M, Berthold, Dopfer R, Gerein V, Ludwing R, Stollmann B, Henze G. Corticosteroid- dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)]. Klin Padiatr. 1987 (May-Jun); 199 (3): 151-160.
Distelhorst CW. Recent insights into the mechanism of glucocorticosteroid induced apoptosis. Cel Dea Diff. 2002; 9: 6-19.
Schrappe M, Beier R, Bürger B. New Treatment Strategies in Childhood Acute Lymphoblastic Leukaemia. Best Pract Res Clin Haematol. 2003; 15: 729-740.
Dordelmann M, Reiter A, Borkhardt A, Ludwing W, Gotz N, Wiehmann S. Prednisone Response is the Strongest Predictor of Treatment Outcome in Infant Acute Lymphoblastic Leukemia. Blood. 1999; 94: 1209-1217.
Gajjar A, Ribeiro R, Hancock M, Rivera G, Mahmoud H, Sandlund J. Persistence of Circulating Blasts After 1 Week of Multiagent Chemoteherapy Confers a Poor Prognosis in Childhood Acute Lymphoblastic Leukemia. Blood. 1995; 86: 1292-1295.
Felice M, Zibizarreta P, Alfaro E, Sackmann-Muriel. Childhood acute lymphoblastic leukemia: prognostic value of initial peripheral blast count in good responders to prednisone. J Pedia Hemat Oncol. 2001; 23: 411-415.
Manabe A, Ohara A, Hasegawa D, Katsuyoshi Koh, Saito T, et al. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children´s Cancer Study Group Study L99-15. Haematologica. 2008; 93: 1155-1160.
Kruth KA, Fang M, Shelton DN, Abu-Halawa O, Mahling R, et al. Suppression of B Cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia. Blood, 2017; 129 (22): 3000- 3008.
Liang Yn, Tang Yl, Ke ZY, Chen YQ, >LUo Xq, et al. Mir-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucorticoid receptor. J steroid Biochem Mol Biol. 2017; 172: 62-68.
Borowitz M, Devidas M, Hunger S, Bowman P, Carroll A, Carroll W. Clinical significance of minimal residual disease in childhood acute lymphoblatic leukemia and its relationship to other prognostic factors: a Children ´s Oncology Group Study. Blood. 2008; 111: 5477- 5485.
Widjajanto PH, Sutaryo S, PruwantoI, Ven PM, Veerman AJ. Early Response to Dexamethasone as Prognostic Factor: Result from Indonesian Childhood WK-ALL Protocol in Yogyakarta. J Oncol. 2012; 41: 1-8.